CA3059265A1 - Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds - Google Patents

Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds Download PDF

Info

Publication number
CA3059265A1
CA3059265A1 CA3059265A CA3059265A CA3059265A1 CA 3059265 A1 CA3059265 A1 CA 3059265A1 CA 3059265 A CA3059265 A CA 3059265A CA 3059265 A CA3059265 A CA 3059265A CA 3059265 A1 CA3059265 A1 CA 3059265A1
Authority
CA
Canada
Prior art keywords
fucosyllactose
subject
compound
day
ibd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3059265A
Other languages
English (en)
French (fr)
Inventor
Ardythe L. Morrow
Lee A. Denson
David S. Newburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of CA3059265A1 publication Critical patent/CA3059265A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3059265A 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds Pending CA3059265A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482840P 2017-04-07 2017-04-07
US62/482,840 2017-04-07
PCT/US2018/026631 WO2018187792A1 (en) 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Publications (1)

Publication Number Publication Date
CA3059265A1 true CA3059265A1 (en) 2018-10-11

Family

ID=63712677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3059265A Pending CA3059265A1 (en) 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Country Status (8)

Country Link
US (2) US20200129534A1 (https=)
EP (1) EP3606535A4 (https=)
JP (3) JP2020513014A (https=)
CN (1) CN110730665A (https=)
AU (2) AU2018250337B2 (https=)
BR (1) BR112019020911A2 (https=)
CA (1) CA3059265A1 (https=)
WO (1) WO2018187792A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021111422A1 (en) * 2019-12-06 2021-06-10 Glycom A/S Composition comprising 2'-fl and dfl for use in a method for reducing pain
CN111698994A (zh) 2017-11-30 2020-09-22 格礼卡姆股份公司 治疗小麦敏感性的hmo混合物
BE1027078A9 (nl) 2019-02-25 2020-09-28 Nutribam Bvba Samenstelling, voedingssupplement en werkwijze voor het ondersteunen en/of verbeteren van de darmgezondheid
WO2020174386A1 (en) 2019-02-25 2020-09-03 Nutribam Bvba Composition, food supplement and method for supporting and/or improving intestinal health
EP4058031A4 (en) * 2019-11-14 2023-11-08 Glycom A/S SYNTHETIC COMPOSITION FOR BALANCING THE BALE ACID PROFILE IN THE INTESTINAL
CN111588726A (zh) * 2020-04-28 2020-08-28 南开大学 2′-岩藻糖基乳糖调节宿主肠道菌群及增强肠屏障的应用
CN116615203B (zh) * 2020-12-11 2025-03-07 帝斯曼知识产权资产管理有限公司 改进的益生元制剂
CN113486954B (zh) * 2021-07-06 2023-04-07 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
WO2023102071A1 (en) * 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
CN119842563B (zh) * 2025-03-17 2025-06-06 昆明医科大学第一附属医院(云南省皮肤病医院) 多尔氏菌emf18-06b1d及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2451462B1 (en) * 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
WO2012009315A2 (en) * 2010-07-12 2012-01-19 The Regents Of The University Of California Bovine milk oligosaccharides
US20120020941A1 (en) * 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
JP6129821B2 (ja) * 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
WO2013154725A1 (en) * 2012-04-13 2013-10-17 Trustees Of Boston College Prebiotic compositions and methods of use
EP2687845A1 (en) * 2012-07-20 2014-01-22 Nestec S.A. Fucose as a biomarker for gut immunity
PL3212198T3 (pl) * 2014-10-29 2021-08-23 Glycom A/S Syntetyczna kompozycja i sposób promowania gojenia się błony śluzowej
AU2016208455A1 (en) * 2015-01-23 2017-06-15 Société des Produits Nestlé S.A. Nutritional composition useful in the treatment of IBD patients
EP3862002A1 (en) * 2015-01-26 2021-08-11 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
US10751354B2 (en) * 2015-09-14 2020-08-25 Glycom A/S Synthetic composition for microbiota modulation

Also Published As

Publication number Publication date
US20200129534A1 (en) 2020-04-30
EP3606535A1 (en) 2020-02-12
US20220133758A1 (en) 2022-05-05
BR112019020911A2 (pt) 2020-05-12
JP2020513014A (ja) 2020-04-30
EP3606535A4 (en) 2020-12-16
AU2024203194A1 (en) 2024-05-30
AU2018250337B2 (en) 2024-02-15
WO2018187792A1 (en) 2018-10-11
JP2025041753A (ja) 2025-03-26
JP2023052629A (ja) 2023-04-11
AU2018250337A1 (en) 2019-10-24
CN110730665A (zh) 2020-01-24

Similar Documents

Publication Publication Date Title
CA3059265A1 (en) Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
Chen et al. The role of butyrate in attenuating pathobiont-induced hyperinflammation
JP2020513014A5 (https=)
Niu et al. Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases
Wędrychowicz et al. Advances in nutritional therapy in inflammatory bowel diseases
Chen et al. Fuzhuan brick tea polysaccharides attenuate metabolic syndrome in high-fat diet induced mice in association with modulation in the gut microbiota
Jiang et al. Mediation of the microbiome-gut axis by oyster (Crassostrea gigas) polysaccharides: A possible protective role in alcoholic liver injury
Lee et al. Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 independent manner
Prantera et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease
Liu et al. The effects and significance of gut microbiota and its metabolites on the regulation of osteoarthritis: Close coordination of gut-bone axis
Wu et al. Chitosan alleviated menopausal symptoms and modulated the gut microbiota in estrogen-deficient rats
Luo et al. Ameliorative effect of purified anthocyanin from Lycium ruthenicum on atherosclerosis in rats through synergistic modulation of the gut microbiota and NF-κB/SREBP-2 pathways
Yang et al. Astragalus polysaccharides-induced gut microbiota play a predominant role in enhancing of intestinal barrier function of broiler chickens
Rotrekl et al. Composites of yeast glucan particles and curcumin lead to improvement of dextran sulfate sodium-induced acute bowel inflammation in rats
Dai et al. Anti-inflammatory effects of newly synthesized α-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice
Lu et al. Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation
Sahu et al. Diet and nutrition in the management of inflammatory bowel disease
CN105394768A (zh) 火龙果酵素营养液及其制备方法
Lv et al. Hepatoprotective effects of magnolol in fatty liver hemorrhagic syndrome hens through shaping gut microbiota and tryptophan metabolic profile
US20170258820A1 (en) Synthetic composition and method for promoting mucosal healing
Feng et al. The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation: a review
Kim et al. Ameliorating effect of 2′-fucosyllactose and 6′-sialyllactose on lipopolysaccharide-induced intestinal inflammation
EP3866615B1 (en) Dietary supplement for treating dysbiosis
Mishra et al. Physiological benefits of Akkermansia muciniphila under high-altitude hypoxia
Zimmermann et al. Consumption of yeast-fermented wheat and rye breads increases colitis and mortality in a mouse model of colitis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240717

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240912

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250211

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250708

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251110